Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Oxaliplatin in ERCC1-low Metastatic Pancreatic Cancer
NCT01524575Phase 2Withdrawn
- Sponsor
- University of Hawaiʻi
- Start
- Jan 2012
- Primary completion
- Jul 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by University of Hawaiʻi. Planned start Jan 2012; status: withdrawn.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01524575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01524575.